Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21457799 | 0.85 | USP28 (0.39) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL7847882 | 0.81 | KDM4E (0.48) | KDM4EALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL4116375 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL20731175 | 0.75 | NOS3 (0.31) | — | |
| SCHEMBL7846665 | 0.74 | MAPT (0.52) | KDM4EALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL7846767 | 0.74 | MEN1 (0.53) | KDM4EALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL23938025 | 0.74 | LIMK1 (0.34) | ALDH1A1L3MBTL1MAPTSMN1; SMN2GAA | |
| SCHEMBL21457814 | 0.74 | KDM4E (0.63) | KDM4EALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL21457816 | 0.74 | USP28 (0.47) | KDM4EALDH1A1MAPTSMN1; SMN2GLA | |
| SCHEMBL7848830 | 0.73 | KDM4E (0.43) | KDM4EALDH1A1L3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3414251-B1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3414251-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139779-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP25, USP28, USP30 | KDM4E 911/4885ALDH1A1 2458/4885POLB 2905/4885 |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | KDM4E 911/4885ALDH1A1 2458/4885POLB 2905/4885 |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | KDM4E 911/4885ALDH1A1 2458/4885POLB 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.